So, roughly 16 days have passed since DECN put its appeal

New Post Public Reply Private Reply Replies (3) Message Board
podcast Bialystock #7946
421
So, roughly 16 days have passed since DECN put its appeal in front of the Federal Circuit court, countered by J&J and two former divisions of J&J. This appeal rises as a result of a ruling by a District Court judge in Nevada who granted J&J a Summary Judgment against DECN's patent infringement claims using an extremely arcane and almost never used implementation of Estoppel. I do not want to go into great detail because patent law is extremely boring, imprecise, and subject to many interpretations. But the Nevada judge's ruling on this was just terrible. Terrible based on his interpretation of the law, and even more terrible because his ruling ended up comparing DECN's invention to itself ---- that is not how patent challenges work nor how patent law is supposed to work.

The Nevada case is of great interest to patent lawyers. First because it involves J&J, the ultimate corporate boogeyman, a reputation richly deserved. Lawyers are guided by their statistics and defeating J&J is much more important for a law firm than defeating DECN. The second reason this case was rich for appeal is because there is no current patent law or previous ruling on the books related to this type of Estoppel challenge. DECN's lawyers would not only slay J&J for a third time, using DECN as their sharp tool, but they would make new law while doing so.

The DECN appeal is very straight forward. The judge was wrong because he applied Estoppel incorrectly, but also because in his application of Estoppel he used J&J's argument almost word for word and never bothered to check whether J&J was arguing correctly, incorrectly, of just full of spam. The Nevada judge took the lazy route and bought J&J's feeble arguments. But because, in my opinion, J&J's arguments leading up to the hearing were so feeble, and wrong, it turned out that J&J was unable to put on much of an oral argument without being laughed out of court. Panel judges in the Federal Circuit know all about patent law, and J&J was left only to argue that the Nevada judge was right.

A lot has been written about the co-called Rule 36. This rule is a favorite of this court because it allows the panel judges to dispose of a case without additional opinion if all three judges in the panel agree that the Nevada judge, in this case, was either correct in his ruling, or close enough to correct that it is not worth spending court resources to get it totally right. This did not happen in the DECN case. There was no "knee jerk" Rule 36, meaning that the judges could not unanimously sustain the lower courts ruling. This means that at least one judge on the panel thinks that DECN won a point, or more. In my humble opinion, and I have been to many of these hearings, I believe that at least two judges will vote in DECN's favor, and I would not be surprised if the entire panel bought DECN's arguments. So I believe that when the written ruling comes down in 6 weeks, and it could be before Christmas, and it might be right after Thanksgiving, I think it would yield a Precidential new law ruling by a vote of 2.5 to .5, one judge, in my opinion Judge Moore voting some in favor, some not in favor. She, to me, did not appear to be totally sold.

On the other hand, if there is only one judge supporting DECN's arguments, there will be another opportunity in about 2-3 weeks for this panel to reconvene and the two already opposed to DECN's arguments could convince the one judge who bought the arguments to change his/her mind, and then Rule 36 it at that time. But this occurrence is so rare that I do not see it happening. I think, in terms of the court, it goes to panel ruling.

Which brings me to handicap things. If the appeal is now to be adjudged at 2.5 to .5, or even 2 to 1, for DECN, it will generate a Precidential ruling over Estoppel, and a rebuke to the Nevada judge. The Precidential ruling is easily valued at $15 million in a settlement, the ruling with a rebuke is easily worth another $10 million for a total of $25 million. Estoppel as it turns out is an expensive part of the law because it has been around for 250 years.

The case taken to trial at the bloody end should be valued at $100 - $125 million. A settlement on the courthouse steps just prior to trial in early 2021 is easily valued at $40 million. But what would it cost to get there. J&J spent about $50 million in its first battles with DECN. They are probably into the current case for $8-$9 million. J&J has already put on most of its case through its summary judgment which is a trial on paper. It is easily foreseeable that they would spend another $25 million to get to trial. And if J&J loses at trial they would have the expense of appeal, another $5 - $10 million.

Nope, J&J will settle this case and they are already feeling the pressure, and the pressure is growing daily. They, as well as anyone, know that their case is weak.

The lack of a short term Rule 36 must be scaring J&J's lawyers a lot. How much will determine when they make a call to DECN. That call will be just after the start of November. In my opinion, of course.

Decision Diagnostics Corp (DECN) Stock Research Links

DECN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 5

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

SAP Launches Sovereign Cloud Solution in Canada for Businesses

Updated Category News Views 365

SAP Enhances Data Security with New Cloud Solutions SAP SE shares are experiencing a positive trend in premarket trading. Recently, SAP Canada introduced its innovative SAP Sovereign Cloud capabilities, which are designed to address the increasing demand from organizations for data sovereignty, robust security, and regulatory compliance. This pioneering solution enables...

Continue Reading
Corbus Pharma's Stock Drops 60%: Analysts Recommend Buying Now

Updated Category News Views 92

Corbus Pharmaceuticals Sees Significant Stock Drop Amid Market Responses Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has recently faced a dramatic decline in its stock, plummeting by an alarming 60%. However, analysts are encouraging investors to view this as a potential buying opportunity. Firms like H.C. Wainwright and Oppenheimer have reaffirmed their buy...

Continue Reading
Manatt Welcomes New Partner with Extensive Investment Expertise

Updated Category News Views 139

Manatt's Strategic Growth in Corporate Practice Manatt, Phelps & Phillips, LLP is making waves in the corporate legal landscape with its recent addition of Peter Tsirigotis, a seasoned investment funds partner. This move reflects the firm's commitment to expanding its financial services and corporate capabilities. Based in Washington, D.C., Tsirigotis brings a wealth of...

Continue Reading
Performance Share Units Vesting: ISS A/S Updates Details

Updated Category News Views 216

Performance Share Units Vesting Announcement ISS A/S is proud to announce the significant milestone concerning its long-term incentive program (LTIP). As part of this initiative, a number of Performance Share Units (PSUs) have recently vested, leading to the delivery of ISS shares to key personnel within the company. This process, which emphasizes the company's commitment...

Continue Reading
Omnicom Boosts Dividend: New Shareholder Benefit Unveiled

Updated Category News Views 196

Omnicom Boosts Dividend for Shareholders Omnicom, a renowned leader in marketing and sales, has officially announced an increase in its quarterly dividend to $0.80 per share. This enhancement reflects a significant increase in the company's commitment to its shareholders, offering both immediate rewards and a long-term strategy for growth. Dividend Increase Overview The...

Continue Reading